Journal of Clinical Oncology, Vol 8, 1630-1636, Copyright © 1990 by American Society of Clinical Oncology
Therapy of renal cell carcinoma with interleukin-2 and lymphokine- activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen
DR Parkinson, RI Fisher, AA Rayner, E Paietta, KA Margolin, GR Weiss, JW Mier, M Sznol, ER Gaynor and MH Bar
National Cancer Institute IL-2/LAK Extramural Working Group, National Cancer Institute, Bethesda, MD 20892.
Forty-seven patients with metastatic or unresectable renal cell carcinoma
were treated with interleukin-2 (IL-2) and lymphokine- activated killer
(LAK)-cell therapy, using a hybrid IL-2 regimen. IL-2 was administered
initially by intravenous bolus (10(5) U/kg [Cetus Corp, Emeryville, CA]
every 8 hours for 3 days) during the priming phase, and subsequently by
continuous infusion (3 x 10(6) U/m2 for 6 days); during this second
treatment period, in vitro-generated LAK cells were administered. Despite
selection of patients for good performance status (PS) (29, PS 0; 18, PS 1)
prior nephrectomy (43 of the 47 patients), and low tumor burden, the
response rate was low (two complete [CRs] and two partial responses [PRs],
for an overall objective response rate of 9%). Toxicity was comparable to
that experienced with the high-dose bolus regimen. These results suggest
that the dose and schedule of IL-2 administration may influence the
likelihood of response to IL-2 in renal cell carcinoma.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Parton, M. Gore, and T. Eisen
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5584 - 5592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Steinman and I. Mellman
Immunotherapy: Bewitched, Bothered, and Bewildered No More
Science,
July 9, 2004;
305(5681):
197 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. Tourani, C. Pfister, N. Tubiana, M. Ouldkaci, G. Prevot, V. Lucas, S. Oudard, M. Malet, P. Cottu, J.-M. Ferrero, et al.
Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design--The Subcutaneous Administration Propeukin Program Cooperative Group
J. Clin. Oncol.,
November 1, 2003;
21(21):
3987 - 3994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Figlin, J. A. Thompson, R. M. Bukowski, N. J. Vogelzang, A. C. Novick, P. Lange, G. D. Steinberg, and A. S. Belldegrun
Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma
J. Clin. Oncol.,
August 1, 1999;
17(8):
2521 - 2521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Negrier, B. Escudier, C. Lasset, J.-Y. Douillard, J. Savary, C. Chevreau, A. Ravaud, A. Mercatello, J. Peny, M. Mousseau, et al.
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
N. Engl. J. Med.,
April 30, 1998;
338(18):
1272 - 1278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Chang, J. D. Geiger, V. K Sondak, and S. Shu
Adoptive Cellular Therapy of Malignancy
Arch Surg,
November 1, 1993;
128(11):
1281 - 1290.
[Abstract]
[PDF]
|
|
|
|
